Skip header and navigation

1 records – page 1 of 1.

Erythropoieis-stimulating agents (ESAs) for people with chronic kidney disease (CKD) and active cancer or a history of cancer or stroke

https://libcat.nshealth.ca/en/permalink/chpams37446
Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2024.
Pamphlet Number
2217
Available Online
View Pamphlet
If you have chronic kidney disease (CKD), your health care provider may order erythropoieis-stimulating agent (ESA) medications for you. This pamphlet explains the risks and benefits of ESAs if you have CKD and active cancer, or a history of cancer or stroke.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Renal Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2024
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([2] p.) : digital, PDF file
Subjects (MeSH)
Renal insufficiency, chronic - complications
Anemia - drug therapy
Hematinics - therapeutic use
Neoplasms
Stroke
Subjects (LCSH)
Chronic renal failure--Complications
Hematopoietic growth factors
Renal anemia--Chemotherapy
Cancer
Cerebrovascular disease
Abstract
If you have chronic kidney disease (CKD), your health care provider may order erythropoieis-stimulating agent (ESA) medications for you. This pamphlet explains the risks and benefits of ESAs if you have CKD and active cancer, or a history of cancer or stroke.
Notes
Previous title: Erythropoieis-stimulating agents (ESAs) for chronic kidney disease (CKD) : with active cancer or a history of cancer or stroke
Responsibility
Prepared by: Renal Program
Pamphlet Number
2217
Less detail